全文获取类型
收费全文 | 107篇 |
免费 | 5篇 |
专业分类
管理学 | 10篇 |
人口学 | 7篇 |
理论方法论 | 12篇 |
综合类 | 1篇 |
社会学 | 76篇 |
统计学 | 6篇 |
出版年
2023年 | 5篇 |
2021年 | 3篇 |
2020年 | 6篇 |
2019年 | 7篇 |
2018年 | 10篇 |
2017年 | 8篇 |
2016年 | 8篇 |
2015年 | 7篇 |
2014年 | 5篇 |
2013年 | 13篇 |
2012年 | 6篇 |
2011年 | 4篇 |
2010年 | 1篇 |
2009年 | 4篇 |
2008年 | 6篇 |
2007年 | 1篇 |
2006年 | 4篇 |
2005年 | 2篇 |
2004年 | 1篇 |
2003年 | 1篇 |
2001年 | 2篇 |
2000年 | 1篇 |
1999年 | 1篇 |
1997年 | 2篇 |
1993年 | 1篇 |
1991年 | 1篇 |
1990年 | 2篇 |
排序方式: 共有112条查询结果,搜索用时 62 毫秒
111.
Using Blinder–Oaxaca decomposition and relying on the consistent design of the Displaced Worker Survey since 1996, this study analyses various factors contributing to the rising dislocation of older workers, such as changes in tenure, industry mix, educational attainment, and labor force participation. Although in the past older workers were less prone to displacement compared with prime‐age workers, this paper finds that older workers are now more likely to be displaced, conditional on education, manufacturing industry, and tenure. Declining tenure, a higher incidence of displacement in manufacturing, and a higher labor force participation among older workers largely explain the convergence of displacement rates among older and prime‐age workers. 相似文献
112.
Stefan Englert François Mercier Elizabeth A. Pilling Victoria Homer Christina Habermehl Stefan Zimmermann Natalia Kan-Dobrosky 《Pharmaceutical statistics》2023,22(5):921-937
The addendum of the ICH E9 guideline on the statistical principles for clinical trials introduced the estimand framework. The framework is designed to strengthen the dialog between different stakeholders, to introduce greater clarity in the clinical trial objectives and to provide alignment between the estimand and statistical analysis. Estimand framework related publications thus far have mainly focused on randomized clinical trials. The intention of the Early Development Estimand Nexus (EDEN), a task force of the cross-industry Oncology Estimand Working Group ( www.oncoestimand.org ), is to apply it to single arms Phase 1b or Phase 2 trials designed to detect a treatment-related efficacy signal, typically measured by objective response rate. Key recommendations regarding the estimand attributes include that in a single arm early clinical trial, the treatment attribute should start when the first dose is received by the participant. Focusing on the estimation of an absolute effect, the population-level summary measure should reflect only the property used for the estimation. Another major component introduced in the ICH E9 addendum is the definition of intercurrent events and the associated possible ways to handle them. Different strategies reflect different clinical questions of interest that can be answered based on the journeys an individual subject can take during a trial. We provide detailed strategy recommendations for intercurrent events typically seen in early-stage oncology. We highlight where implicit assumptions should be made transparent as whenever follow-up is suspended, a while-on-treatment strategy is implied. 相似文献